This inventor holds 2 USPTO granted patents and 1 published patent application. Top assignees: Chinese Academy of Sciences, Kunming Institute of Botany. Active years: 2015-2024.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
Company Filing History:

Years Active: 2015-2024
Title: Xianghai Cai: Innovator in Pharmaceutical Science
Introduction
Xianghai Cai is a prominent inventor based in Kunming, China. He has made significant contributions to the field of medicine through his innovative research and development of pharmaceutical compounds. With a total of 2 patents, his work focuses on enhancing immune responses and developing treatments for various cancers.
Latest Patents
Cai's latest patents include the "Furan-aspidospermine dimer or pharmaceutically acceptable salt thereof, and preparation method, use and pharmaceutical composition." This invention relates to a compound that can activate an immune response by increasing the proportion of T lymphocytes, thereby enhancing immune function. Another notable patent is for "melonine bisindole compounds, pharmaceutical compositions, preparation method and use thereof." This invention pertains to melonine bisindole compounds and their application in the manufacture of medicaments for cancer treatment or prophylaxis.
Career Highlights
Throughout his career, Xianghai Cai has worked with esteemed institutions such as the Chinese Academy of Sciences and the Kunming Institute of Botany. His research has significantly impacted the pharmaceutical field, particularly in developing new therapeutic agents.
Collaborations
Cai has collaborated with notable colleagues, including Guisheng Zhong and Yaping Liu. These partnerships have fostered a collaborative environment that enhances the innovation process in pharmaceutical research.
Conclusion
Xianghai Cai's contributions to pharmaceutical science through his patents and collaborations highlight his role as a key innovator in the field. His work continues to pave the way for advancements in medical treatments and therapies.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile